These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 18061446)

  • 41. 4-Anilino-7-alkenylquinoline-3-carbonitriles as potent MEK1 kinase inhibitors.
    Berger DM; Dutia M; Powell D; Floyd MB; Torres N; Mallon R; Wojciechowicz D; Kim S; Feldberg L; Collins K; Chaudhary I
    Bioorg Med Chem; 2008 Oct; 16(20):9202-11. PubMed ID: 18815050
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biphenyl amide p38 kinase inhibitors 2: Optimisation and SAR.
    Angell RM; Angell TD; Bamborough P; Brown D; Brown M; Buckton JB; Cockerill SG; Edwards CD; Jones KL; Longstaff T; Smee PA; Smith KJ; Somers DO; Walker AL; Willson M
    Bioorg Med Chem Lett; 2008 Jan; 18(1):324-8. PubMed ID: 17981461
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
    Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
    J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Design, synthesis, and biological evaluation of potent c-Met inhibitors.
    D'Angelo ND; Bellon SF; Booker SK; Cheng Y; Coxon A; Dominguez C; Fellows I; Hoffman D; Hungate R; Kaplan-Lefko P; Lee MR; Li C; Liu L; Rainbeau E; Reider PJ; Rex K; Siegmund A; Sun Y; Tasker AS; Xi N; Xu S; Yang Y; Zhang Y; Burgess TL; Dussault I; Kim TS
    J Med Chem; 2008 Sep; 51(18):5766-79. PubMed ID: 18763753
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
    Li HY; McMillen WT; Heap CR; McCann DJ; Yan L; Campbell RM; Mundla SR; King CH; Dierks EA; Anderson BD; Britt KS; Huss KL; Voss MD; Wang Y; Clawson DK; Yingling JM; Sawyer JS
    J Med Chem; 2008 Apr; 51(7):2302-6. PubMed ID: 18314943
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.
    Gomez HL; Doval DC; Chavez MA; Ang PC; Aziz Z; Nag S; Ng C; Franco SX; Chow LW; Arbushites MC; Casey MA; Berger MS; Stein SH; Sledge GW
    J Clin Oncol; 2008 Jun; 26(18):2999-3005. PubMed ID: 18458039
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases.
    Dandu R; Zulli AL; Bacon ER; Underiner T; Robinson C; Chang H; Miknyoczki S; Grobelny J; Ruggeri BA; Yang S; Albom MS; Angeles TS; Aimone LD; Hudkins RL
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1916-21. PubMed ID: 18308565
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.
    Chao Q; Sprankle KG; Grotzfeld RM; Lai AG; Carter TA; Velasco AM; Gunawardane RN; Cramer MD; Gardner MF; James J; Zarrinkar PP; Patel HK; Bhagwat SS
    J Med Chem; 2009 Dec; 52(23):7808-16. PubMed ID: 19754199
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthesis and structure-activity relationships of N-6 substituted analogues of 9-hydroxy-4-phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of Wee1 and Chk1 checkpoint kinases.
    Smaill JB; Baker EN; Booth RJ; Bridges AJ; Dickson JM; Dobrusin EM; Ivanovic I; Kraker AJ; Lee HH; Lunney EA; Ortwine DF; Palmer BD; Quin J; Squire CJ; Thompson AM; Denny WA
    Eur J Med Chem; 2008 Jun; 43(6):1276-96. PubMed ID: 17869387
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors.
    Jin M; Wang J; Kleinberg A; Kadalbajoo M; Siu KW; Cooke A; Bittner MA; Yao Y; Thelemann A; Ji Q; Bhagwat S; Mulvihill KM; Rechka JA; Pachter JA; Crew AP; Epstein D; Mulvihill MJ
    Bioorg Med Chem Lett; 2013 Feb; 23(4):979-84. PubMed ID: 23317569
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Design, synthesis, and biological evaluation of pyridoquinazoline derivatives as potent epidermal growth factor receptor inhibitors.
    Rani S; Sridhar L; Srivastava R; Singh VK
    Cancer Biother Radiopharm; 2013; 28(6):494-9. PubMed ID: 23641780
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
    J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
    Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
    Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery of 2-chloro-N-(4-methoxyphenyl)-N-methylquinazolin-4-amine (EP128265, MPI-0441138) as a potent inducer of apoptosis with high in vivo activity.
    Sirisoma N; Kasibhatla S; Pervin A; Zhang H; Jiang S; Willardsen JA; Anderson MB; Baichwal V; Mather GG; Jessing K; Hussain R; Hoang K; Pleiman CM; Tseng B; Drewe J; Cai SX
    J Med Chem; 2008 Aug; 51(15):4771-9. PubMed ID: 18651728
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design and synthesis of a novel, orally active, brain penetrant, tri-substituted thiophene based JNK inhibitor.
    Bowers S; Truong AP; Neitz RJ; Neitzel M; Probst GD; Hom RK; Peterson B; Galemmo RA; Konradi AW; Sham HL; Tóth G; Pan H; Yao N; Artis DR; Brigham EF; Quinn KP; Sauer JM; Powell K; Ruslim L; Ren Z; Bard F; Yednock TA; Griswold-Prenner I
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1838-43. PubMed ID: 21316234
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44.
    Liu FJ; Gui SB; Li CZ; Sun ZL; Zhang YZ
    Chin Med J (Engl); 2008 Sep; 121(17):1702-6. PubMed ID: 19024103
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88
    Degorce SL; Anjum R; Bloecher A; Carbajo RJ; Dillman KS; Drew L; Halsall CT; Lenz EM; Lindsay NA; Mayo MF; Pink JH; Robb GR; Rosen A; Scott JS; Xue Y
    J Med Chem; 2019 Nov; 62(21):9918-9930. PubMed ID: 31622099
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-lineage kinase 1 crystallography, and oral in vivo activity in 1-methyl-4-phenyltetrahydropyridine models.
    Hudkins RL; Diebold JL; Tao M; Josef KA; Park CH; Angeles TS; Aimone LD; Husten J; Ator MA; Meyer SL; Holskin BP; Durkin JT; Fedorov AA; Fedorov EV; Almo SC; Mathiasen JR; Bozyczko-Coyne D; Saporito MS; Scott RW; Mallamo JP
    J Med Chem; 2008 Sep; 51(18):5680-9. PubMed ID: 18714982
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines.
    Gaul MD; Guo Y; Affleck K; Cockerill GS; Gilmer TM; Griffin RJ; Guntrip S; Keith BR; Knight WB; Mullin RJ; Murray DM; Rusnak DW; Smith K; Tadepalli S; Wood ER; Lackey K
    Bioorg Med Chem Lett; 2003 Feb; 13(4):637-40. PubMed ID: 12639547
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors.
    Gerspacher M; Furet P; Pissot-Soldermann C; Gaul C; Holzer P; Vangrevelinghe E; Lang M; Erdmann D; Radimerski T; Regnier CH; Chene P; De Pover A; Hofmann F; Baffert F; Buhl T; Aichholz R; Blasco F; Endres R; Trappe J; Drueckes P
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1724-7. PubMed ID: 20138510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.